We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Sep 26, we issued an updated research report on Edwards Lifesciences Corporation (EW - Free Report) . The stock currently carries a Zacks Rank #3 (Hold).
Over the last six months, this leading molecular diagnostic company has been trading above the broader industry. The stock has gained 15.3% in this period, higher than the broader industry’s 11.5% gain. The recent FDA approvals for several products including SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve seem to be bolstering investors’ confidence on the stock.
Also, the raised guidance for 2017 hints at brighter prospects. In fact, the outlook raise was backed by strong performance of all of the company’s three product lines.
We are encouraged by the company’s long-term growth strategies and recent progress in its technology pipeline. As far as transcatheter heart valve (THV) is concerned, Edwards Lifesciences expects to maintain its leadership position in the global Transcatheter Aortic Valve Replacement (TAVR) market.
Also, the company’s focus on building its pipeline to strengthen its foothold across all operating businesses bodes well. Edwards Lifesciences has also witnessed growth in its emerging portfolio of mitral and tricuspid repair therapies.
On the flip side, foreign exchange headwinds continue to mar the company’s international business. Also, a competitive landscape in the overseas market weighs on the company’s prospects.
Key Picks
A few better-ranked medical stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Owens & Minor, Inc. (OMI - Free Report) and OraSure Technologies, Inc. (OSUR - Free Report) . Orthofix International and Owens & Minor sport a Zacks Rank #1 (Strong Buy), while OraSure Technologies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 3% over the last three months.
Owens & Minor has a long-term expected earnings growth rate of 5%. The stock has gained 4.4% over the last month.
OraSure Technologies has a long-term expected earnings growth rate of 16%. The stock has gained 9.1% over the last month.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Edwards Lifesciences Pipeline Impressive, Currency Woes Stay
On Sep 26, we issued an updated research report on Edwards Lifesciences Corporation (EW - Free Report) . The stock currently carries a Zacks Rank #3 (Hold).
Over the last six months, this leading molecular diagnostic company has been trading above the broader industry. The stock has gained 15.3% in this period, higher than the broader industry’s 11.5% gain. The recent FDA approvals for several products including SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve seem to be bolstering investors’ confidence on the stock.
Also, the raised guidance for 2017 hints at brighter prospects. In fact, the outlook raise was backed by strong performance of all of the company’s three product lines.
We are encouraged by the company’s long-term growth strategies and recent progress in its technology pipeline. As far as transcatheter heart valve (THV) is concerned, Edwards Lifesciences expects to maintain its leadership position in the global Transcatheter Aortic Valve Replacement (TAVR) market.
Also, the company’s focus on building its pipeline to strengthen its foothold across all operating businesses bodes well. Edwards Lifesciences has also witnessed growth in its emerging portfolio of mitral and tricuspid repair therapies.
On the flip side, foreign exchange headwinds continue to mar the company’s international business. Also, a competitive landscape in the overseas market weighs on the company’s prospects.
Key Picks
A few better-ranked medical stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Owens & Minor, Inc. (OMI - Free Report) and OraSure Technologies, Inc. (OSUR - Free Report) . Orthofix International and Owens & Minor sport a Zacks Rank #1 (Strong Buy), while OraSure Technologies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 3% over the last three months.
Owens & Minor has a long-term expected earnings growth rate of 5%. The stock has gained 4.4% over the last month.
OraSure Technologies has a long-term expected earnings growth rate of 16%. The stock has gained 9.1% over the last month.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>